Specifically, the law amends requirements that state-licensed medical cannabis producers and distributors be limited to providing patients with no more than three strains of the plant – a regulatory rule that has been in place since the program’s inception some three years ago. Proponents of the rule change argued that lifting the three-strain cap will foster the production and distribution of varieties of cannabis high in CBD (cannabidiol) content. Cannabidiol is a non-psychotropic cannabinoid that possesses a variety of therapeutic properties. However, it is typically present only at low levels in conventional strains of marijuana, which typically are bred to possess higher quantities of THC – the primary psychoactive ingredient in cannabis.
Senate Bill 2842 also allows for cannabis distributors to produce marijuana-infused edible products. However, at the insistence of the Governor, consumption of such products will be limited to those aged under 18.
The Governor previously vetoed language that sought to streamline regulations so that qualified patients under the age of 18 could more readily access medicinal cannabis.
Under present New Jersey law, authorized patients may only obtain medical cannabis from state-licensed dispensaries. To date, however, few facilities are actively up and running. Earlier this month, the state’s Economic Developmental Authority approved a $375,000 loan to the Compassionate Care Foundation dispensary, which plans to open its doors in mid-October.
For more information, please contact Allen St. Pierre, NORML Executive Director or Erik Altieri, NORML Communications Director, at (202) 483-5500.